Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Computer image of human kidneys being damaged by infection

Urinary Biomarkers Predict Severe Kidney Injury in Patients with COVID-19

Researchers found that certain biomarkers were associated with stage 3 AKI, dialysis, and death

National Kidney Foundation

Fueled by passion and urgency, National Kidney Foundation is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, NKF focuses on the whole patient through the lens of kidney health. Relentless in our work, we enhance lives through action, education and accelerating change.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Oct 26, 2021
|1 min read
Register for free to listen to this article
Listen with Speechify

In this study published in the American Journal of Kidney Diseases (AJKD), researchers found that two-fold higher levels of neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein, and kidney injurymolecule-1 were associated with increased risk of severe acute kidney injury or death in patients hospitalized with COVID-19. 

Acute kidney injury (AKI) is a serious complication in patients hospitalized with COVID-19. Researchers hypothesized that biomarkers measured in the urine that are more specific for kidney injury and inflammation than serum creatinine may add to the understanding of kidney injury in the setting of COVID-19. They found that certain biomarkers including epidermal growth factor and kidney injury molecule-1, among others, were associated with stage 3 AKI, dialysis, and death up to 60 days in patients hospitalized with COVID-19. These study results suggest that these studied biomarkers may help identify patients at particularly high risk for adverse kidney outcomes.

- This press release was provided by the National Kidney Foundation